The Chemotherapy Induced Peripheral Neuropathy Pipeline Insight report from DelveInsight offers a detailed overview of the pipeline therapies in various clinical and preclinical stages of growth, their introduction, and how the Chemotherapy Induced Peripheral Neuropathy market is expected to change as a result.
The Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis report gives you a complete picture of the Chemotherapy Induced Peripheral Neuropathy therapeutic landscape, including development stage, product type, route of administration, molecule type, and MOA.
The report addresses a wide range of topics, including market opportunities, challenges, future alliances, strong competitors, and growth strategies.
Some of the Key Highlights from the Chemotherapy Induced Peripheral Neuropathy Market Report
There are more than 30+ Chemotherapy Induced Peripheral Neuropathy pipeline therapies in different stages of development, and their expected adoption in the Chemotherapy Induced Peripheral Neuropathy market will significantly increase market revenue.
Out of the emerging therapies, Tetrodotoxin and PledOx are in Phase III of clinical development, whereas MP-101 and Ibudilast are in Phase II development phase for Chemotherapy Induced Peripheral Neuropathy.
Chemotherapy Induced Peripheral Neuropathy pipeline therapies in the early stage of development include Ricolinostat and APX 3330 in Phase I of clinical trials.
Some Chemotherapy Induced Peripheral Neuropathy pipeline therapy which is still in the pre-clinical stage of development include AM 1710.
For more information request sample @ Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis
Chemotherapy Induced Peripheral Neuropathy: Disease Overview
Taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon all cause Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a normal, dose-dependent side effect of many commonly prescribed chemotherapy and biotherapy drugs. CIPN causes a wide range of symptoms, including physical and emotional discomfort from neuropathic pain, as well as degeneration.
Chemotherapy Induced Peripheral Neuropathy: Symptoms
Exaggerated sensation (neuropathic pain), loss of sensation (numbness, muscle weakness, loss of balance), or both are symptoms of CIPN. Symptoms are normally bilateral and develop in a distal to proximal pattern, starting at the tips of the fingers and toes and progressing to the upper and/or lower extremities.
Chemotherapy Induced Peripheral Neuropathy: Treatment
However, there are no licenced medications to prevent or treat CIPN at this time. Some chemotherapy medications have a higher risk of causing neuropathy. Platinum medications like oxaliplatin, taxanes like docetaxel, vinca alkaloids like vincristine, and myeloma therapies like bortezomib are among them. Neuropathy can also be caused by other chemotherapy medications.
Learn more about CIPN @ CIPN Market Trends
Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis: Drug Profile
Pledox (Calmangafodipir): Egetis Therapeutics
PledOx (also known as calmangafodipir, SP-04) is a first-in-class drug candidate being developed by Pledpharma for the prevention of nerve damage caused by chemotherapy in colorectal cancer patients. Calmangafodipir is currently in Phase III clinical trials for the prevention of chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) caused by the drug Oxaliplatin in patients with cancer.
Chemotherapy Induced Peripheral Neuropathy Pipeline Therapies and Major Companies
Tetrodotoxin: WEX Pharmaceuticals
PledOx: Egetis Therapeutics
MP-101: Metys Pharmaceuticals AG
Ibudilast: MediciNova
Ricolinostat: Regenacy pharmaceuticals
APX 3330: Apexian Pharmaceuticals
AM 1710: MakScientific
Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Key CIPN Players: WEX Pharmaceuticals, Egetis Therapeutics, Metys Pharmaceuticals AG, MediciNova, Regenacy pharmaceuticals, Apexian Pharmaceuticals, MakScientific, among others.
Key CIPN Pipeline Therapies: Tetrodotoxin, PledOx, MP-101, Ibudilast, Ricolinostat, APX 3330, AM 1710, others.
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Chemotherapy Induced Peripheral Neuropathy: Overview
4.
Chemotherapy Induced Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment
5.
Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics
6.
CIPN Late Stage Products (Phase III)
7.
CIPN Mid Stage Products (Phase II)
8.
CIPN Early Stage Products (Phase I)
9.
CIPN Preclinical Stage Products
10.
CIPN Therapeutic Assessment
11.
CIPN Inactive Products
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Chemotherapy Induced Peripheral Neuropathy Key Companies
14.
Chemotherapy Induced Peripheral Neuropathy Key Products
15.
Chemotherapy Induced Peripheral Neuropathy- Unmet Needs
16.
Chemotherapy Induced Peripheral Neuropathy- Market Drivers and Barriers
17.
Chemotherapy Induced Peripheral Neuropathy- Future Perspectives and Conclusion
18.
CIPN Analyst Views
19.
Appendix
20.
About DelveInsight
Get in touch with our Business executive @ Chemotherapy Induced Peripheral Neuropathy Pipeline Insights to know more
Key Questions Answered in the Chemotherapy Induced Peripheral Neuropathy Report
What treatment options are available for Chemotherapy-Induced Peripheral Neuropathy?
How many companies are working on treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN)?
What are the main therapies that these companies in the industry have developed?
How many therapies are being developed for the treatment of Chemotherapy Induced Peripheral Neuropathy by each company?
How many Chemotherapy Induced Peripheral Neuropathy emerging therapies are in progress for the treatment of Chemotherapy Induced Peripheral Neuropathy at the early, mid, and late stages?
How many therapies are offered as monotherapies and in conjunction with other therapies out of the total pipeline products?
What are the main industry-industry and industry-academia partnerships, mergers and acquisitions, and major licencing activities that will have an effect on Chemotherapy Induced Peripheral Neuropathy?
Related Reports
Chemotherapy Induced Nausea and Vomiting Market
Get comprehensive historical and forecast analysis of Chemotherapy Induced Nausea and Vomiting Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/